The content on this website has been developed solely by Celgene.

DOSAGE & ADMINISTRATION:
PEMBROLIZUMAB WITH ABRAXANE + CARBOPLATIN12

Pembrolizumab (See the pembrolizumab PI for recommended dosing) + ABRAXANE 100 mg/m2 + carboplatin AUC 6 mg•min/mL
ILLUSTRATIVE PURPOSES ONLY
  • When administering pembrolizumab in combination with chemotherapy, pembrolizumab should be administered prior to chemotherapy when given on the same day
  • Administer pembrolizumab on Day 1 of each 21-day cycle
  • Administer ABRAXANE intravenously at a dose of 100 mg/m² over 30 minutes on a weekly schedule onDays 1, 8, and 15 of each 21-day cycle
  • Administer carboplatin intravenously on Day 1 of each 21-day cycle immediately after completion of ABRAXANE administration
See the Prescribing Information for pembrolizumab administered in combination with ABRAXANE and carboplatin.
Note: An albumin form of paclitaxel may substantially affect a drug’s functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS.
  • Severe hypersensitivity reactions with fatal outcome have been reported with ABRAXANE. Patients who experiencea severe hypersensitivity reaction to ABRAXANE should not be rechallenged with this drug
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL